There are two different sources of IL-6 in MM that promote tumor development and maintenance in vivo: autocrine IL-6 derived from myeloma cells [6–9] and paracrine IL-6 derived from non-malignant cells of the BM niche [10–12]. This evidence concerns the gene IL6 and plasma cell myeloma.